Korea BNC Partners With Dongkook For Bienox Distribution

Korea BNC has signed an exclusive distribution agreement with Dongkook Pharmaceutical for its botulinum toxin product, Bienox. Approved by the Ministry of Food and Drug Safety in March 2024, Bienox is used in aesthetic treatments to reduce frown lines temporarily.

Working in collaboration will benefit both companies in navigating the development of marketing strategies and new customers. Korea BNC is now initiating domestic sales for Bienox and supporting Dongkook Pharmaceutical's cosmetic solid and aesthetic medicine industry presence. They are also exploring international export opportunities. 

A Korea BNC official said, “We anticipate initiating product orders and supplying Bienox for local sales as early as this year.”

Dongkook has recently introduced several new products, like the hyaluronic acid filler Kablelyn, skin booster De. hive, and the wound care line Madeca MD Cream and Lotion.